Volume 30, No 10, Oct 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 10, October 2020: 932-935

LETTERS TO THE EDITOR

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

Wanbo Tai¹ , Xiujuan Zhang¹ , Aleksandra Drelich² , Juan Shi¹ , Jason C. Hsu² , Larry Luchsinger¹ , Christopher D. Hillyer¹ , Chien-Te K. Tseng² , Shibo Jiang^1,* , Lanying Du¹

¹Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
²Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA
These authors contributed equally: Wanbo Tai, Xiujuan Zhang Correspondence: Shibo Jiang(ldu@nybc.org)

Dear Editor,

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the need to develop effective and safe vaccines. Similar to SARS-CoV, SARS-CoV-2 recognizes angiotensin-converting enzyme 2 (ACE2) as receptor for host cell entry.1,2 SARS-CoV-2 spike (S) protein consists of S1, including receptor-binding domain (RBD), and S2 subunits.3,4 We previously demonstrated that RBDs of SARS-CoV and MERS-CoV serve as important targets for the development of effective vaccines.5,6

https://doi.org/10.1038/s41422-020-0387-5

FULL TEXT | PDF

Browse 1079